全文获取类型
收费全文 | 1550篇 |
免费 | 177篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 34篇 |
妇产科学 | 10篇 |
基础医学 | 184篇 |
口腔科学 | 22篇 |
临床医学 | 130篇 |
内科学 | 419篇 |
皮肤病学 | 13篇 |
神经病学 | 94篇 |
特种医学 | 32篇 |
外科学 | 194篇 |
综合类 | 49篇 |
预防医学 | 91篇 |
眼科学 | 21篇 |
药学 | 112篇 |
中国医学 | 15篇 |
肿瘤学 | 297篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 18篇 |
2021年 | 28篇 |
2020年 | 17篇 |
2019年 | 53篇 |
2018年 | 49篇 |
2017年 | 55篇 |
2016年 | 49篇 |
2015年 | 50篇 |
2014年 | 66篇 |
2013年 | 87篇 |
2012年 | 98篇 |
2011年 | 139篇 |
2010年 | 64篇 |
2009年 | 90篇 |
2008年 | 97篇 |
2007年 | 87篇 |
2006年 | 82篇 |
2005年 | 97篇 |
2004年 | 139篇 |
2003年 | 94篇 |
2002年 | 68篇 |
2001年 | 42篇 |
2000年 | 22篇 |
1999年 | 17篇 |
1998年 | 10篇 |
1997年 | 5篇 |
1996年 | 8篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 13篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 5篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1978年 | 6篇 |
1977年 | 3篇 |
1971年 | 3篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有1730条查询结果,搜索用时 0 毫秒
41.
Buxton DB Lee SC Wickline SA Ferrari M;National Heart Lung Blood Institute Nanotechnology Working Group 《Circulation》2003,108(22):2737-2742
Recent rapid advances in nanotechnology and nanoscience offer a wealth of new opportunities for diagnosis and therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders. To review the challenges and opportunities offered by these nascent fields, the National Heart, Lung, and Blood Institute convened a Working Group on Nanotechnology. Working Group participants discussed the various aspects of nanotechnology and its applications to heart, lung, blood, and sleep (HLBS) diseases. This report summarizes their discussions according to scientific opportunities, perceived needs and barriers, specific disease examples, and recommendations on facilitating research in the field. An overarching recommendation of the Working Group was to focus on translational applications of nanotechnology to solve clinical problems. The Working Group recommended the creation of multidisciplinary research centers capable of developing applications of nanotechnology and nanoscience to HLBS research and medicine. Centers would also disseminate technology, materials, and resources and train new investigators. Individual investigators outside these centers should be encouraged to conduct research on the application of nanotechnology to biological and clinical problems. Pilot programs and developmental research are needed to attract new investigators and to stimulate creative, high-impact research. Finally, encouragement of small businesses to develop nanotechnology-based approaches to clinical problems was considered important. 相似文献
42.
Laparoscopic rectopexy for recurrent volvulus of J pouch after total proctocolectomy and ileal pouch anal anastomosis 下载免费PDF全文
Suet‐Ying Lee Ka‐Lung Fok Hester Yui‐Shan Cheung Chung‐Ngai Tang 《Surgical Practice》2015,19(3):133-136
Ileal‐pouch anal anastomosis (IPAA) is most commonly performed after total proctocolectomy for ulcerative colitis and familial adenomatous polyposis. Small‐bowel obstruction is one of the complications that can occur years after the operation, but intestinal obstruction due to volvulus of the J pouch is a rare condition. We report a case of recurrent volvulus in a patient who had undergone IPAA after total proctocolectomy for cancer of the rectum and multiple colonic polyps. The patient underwent laparoscopic rectopexy and had no recurrence of volvulus. 相似文献
43.
Kwan‐Lung Ko Wai‐Pan To Lung‐Yi Mak Wai‐Kay Seto Qin Ning James Fung Ching‐Lung Lai Man‐Fung Yuen 《Journal of viral hepatitis》2020,27(4):397-406
Real‐world studies examining reduction in risk of hepatocellular carcinoma (HCC) in patients receiving antivirals are limited by the small size of the studies, or by data insufficiency and heterogeneity with short follow‐up duration. We aimed to examine the real‐world long‐term outcome of patients receiving entecavir treatment on HCC incidence and HBsAg seroclearance. The incidence of HCC in 1225 entecavir‐treated patients between 2002 and 2015 was compared with the HCC incidence estimated using the REACH‐B, GAG‐HCC and CU‐HCC scores. Standardized incidence ratios (SIR) were calculated. The impact of entecavir treatment on HBsAg seroclearance was also explored. The median follow‐up of the cohort was 6.6 years, with 66 cases of HCC development. Using the REACH‐B model, the reduction of HCC risk was significant from year 6 onwards with SIR of 0.68 (95% CI 0.535‐0.866) at year 10. In subgroup patients without cirrhosis, consistent risk reduction was observed from the fifth year and the SIR reached 0.51 (95% CI 0.271‐0.704) by year 10. Benefit in cirrhotic patients was demonstrated when using the GAG‐HCC and CU‐HCC score, with the SIR at year 10 being 0.38 (95% CI 0.259‐0.544) and 0.46 (95% CI 0.314‐0.659), respectively. The cumulative rate of HBsAg seroclearance was 5.2%. HBsAg level at third year of treatment and baseline‐to‐3‐year percentage reduction was predictive of subsequent HBsAg seroclearance. In conclusion, long‐term entecavir therapy was associated with significant reduction in the risk of HCC in the real world. However, HBsAg seroclearance rate remained low. Additional therapy may be considered in patients with adverse predictive factors for subsequent HBsAg seroclearance. 相似文献
44.
45.
46.
47.
48.
49.